CCL22 and neoplasm: In an in situ PDAC mouse models, spMEXO could exert potential therapeutic effects by promoting the maturation of DCs, activation of CTLs, secretion of anti-tumor cytokines and blocking recruitment of Tregs by DCs through the CCR4/CCL22 axis, successfully inhibiting tumor growth.